-
Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice
Sep 9, 2025, 16:22 PM -
Five-Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of AI-Assisted Ultrasound for Breast Cancer Detection in Taiwan
Sep 9, 2025, 16:22 PM -
Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective
Sep 9, 2025, 16:22 PM -
Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025
Sep 9, 2025, 16:22 PM -
Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing
Sep 9, 2025, 16:22 PM -
Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study
Sep 9, 2025, 16:22 PM -
Trends in Hospitalizations and Amputations in Diabetic Foot Ulcers (DFUs) in Germany 2019 to 2024
Sep 9, 2025, 16:22 PM -
Impact Of Dupilumab Treatment on Work-Related Medical Leave In Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer
Sep 9, 2025, 16:22 PM -
Lifetime Secondary Healthcare Resource Utilization in Phenylketonuria From Birth to Adulthood in Sweden
Sep 9, 2025, 16:22 PM -
Impact of the COVID-19 Pandemic on Healthcare Expenditure
Sep 9, 2025, 16:22 PM -
Care of Patients With Phenylketonuria (PKU) in Germany a Claims Data Analysis From 2013 to 2023
Sep 9, 2025, 16:22 PM -
The Uptake of R in NICE HTA: Insights From Technology Assessment Groups
Sep 9, 2025, 16:22 PM -
Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium
Sep 9, 2025, 16:22 PM -
Cost of Illness Studies Published Between 2010 and 2023 in Türkiye
Sep 9, 2025, 16:22 PM -
Estimating Healthcare Resource Use Associated With the Treatment of Phenylketonuria in the United States
Sep 9, 2025, 16:22 PM -
Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine
Sep 9, 2025, 16:22 PM -
APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes
Sep 9, 2025, 16:22 PM -
What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?
Sep 9, 2025, 16:22 PM
